- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05069831
JAK Inhibition in Food Allergy
Study Overview
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Yair Bitton, MBA, MPH
- Phone Number: 347-466-2547
- Email: yair.bitton@mssm.edu
Study Contact Backup
- Name: Scott Sicherer, MD
- Email: scott.sicherer@mssm.edu
Study Locations
-
-
New York
-
New York, New York, United States, 10029
- Recruiting
- Icahn School of Medicine at Mount Sinai
-
Contact:
- Yair Bitton, MBA, MPH
- Email: yair.bitton@mssm.edu
-
Contact:
- Scott Sicherer
- Email: scott.sicherer@mssm.edu
-
Principal Investigator:
- Scott Sicherer, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- 18 - 50 years old
- Participant must be able to understand and perform informed consent.
IgE-mediated food allergy to at least one of the following foods as defined by (regarding at least one of the foods):
° Foods: peanut, cashew, walnut, hazelnut, sesame, cod, and/or shrimp, history of an acute allergic reaction (urticaria, angioedema, cough, wheeze, and/or repetitive vomiting within an hour of ingestion, and history of positive skin or serum IgE test, and current strict avoidance of the food, and current possession of physician-prescribed self-injectable epinephrine, and skin test wheal 5 mm or greater average diameter
- Current or past eczema.
- If female of childbearing potential, must have a negative pregnancy test (serum or urine) and agree to abstinence or acceptable contraception.
- Plan to remain in the Tri-State area during the trial for visits.
- Must agree to avoid prolonged exposure to the sun and not to use tanning booths, sunlamps, or other ultraviolet (UV) light sources during the study.
- If receiving concomitant medications for any reason other than AD, must be on a stable regimen, which is defined as not starting a new drug or changing dosage within 7 days or 5 half-lives (whichever is longer) prior to Day 1 and through the duration of the study.
Exclusion Criteria:
- Unwilling or unable to give written informed consent or comply with protocol.
- Unable to swallow pill.
- Use of dupilumab within 6 weeks of enrollment.
- Prior use or allergy to drugs related to abrocitinib (ruxolitinib, upadacitinib, etc).
- Use of any other biologic (monoclonal antibody) medication within 12 weeks or 5 half-lives of drug, if known.
- Allergy to any excipients within abrocitinib.
- Use of build-up environmental immunotherapy; any food oral immunotherapy;or systemic oral, IV or IM steroids including but not limited to- prednisone, methylprednisolone, prednisolone, solumedrol, solucortef, dexamethasone in the past 4 weeks or 5 half-lives of drug, if known.
- Use of CYP2C9 and CYP2C19 inducers (such as carbamazepine, norfluoxetine, etc.) within 5 half-lives of the inducer plus 14 days prior to the first dose of study intervention.
- Use of CYP2C9 and CYP2C19 inhibitors within 1 week of first dose of study intervention or within 5 half-lives (if known) of the inhibitor, whichever is longer.
- Unable to stop long-acting antihistamines within minimum wash out period required for SPTs at screening and site visits
- History of or significant risk factor(s) for cardiovascular disease
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Abrocitinib 100mg
This arm will receive 100mg of the study drug
|
Abrocitinib daily for 4 months
|
Active Comparator: Abrocitinib 200mg
This arm will receive 200mg of the study drug
|
Abrocitinib daily for 4 months
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
change in basophil activation
Time Frame: baseline and after 4 months of treatment
|
change in basophil activation as measured by %CD63 AUC
|
baseline and after 4 months of treatment
|
change in skin prick test
Time Frame: baseline and after 4 months of treatment
|
change in skin prick test size after four months of therapy.
|
baseline and after 4 months of treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
change in antigen-specific T-cell
Time Frame: baseline and after 4 months of treatment
|
change in antigen-specific T-cell response
|
baseline and after 4 months of treatment
|
change in specific immunoglobulin E (sIgE)
Time Frame: baseline and after 4 months of treatment
|
change in sIgE to allergic trigger food(s)
|
baseline and after 4 months of treatment
|
change in FENO
Time Frame: baseline and after 4 months of treatment
|
Fractional Exhaled Nitric Oxide (FeNO) level
|
baseline and after 4 months of treatment
|
Collaborators and Investigators
Investigators
- Study Chair: Scott Sicherer, MD, Icahn School of Medicine at Mount Sinai
- Principal Investigator: Emma Guttman, MD, PhD, Icahn School of Medicine at Mount Sinai
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- GCO 21-0781
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Food Allergy
-
Vilnius UniversityEnrolling by invitationFood Allergy in Children | Food Allergy in InfantsLithuania
-
Vilnius UniversityEnrolling by invitationFood Allergy in Children | Food Allergy in InfantsLithuania
-
Assistance Publique Hopitaux De MarseilleUnknown
-
Chinese University of Hong KongRecruiting
-
King's College LondonKing's College Hospital NHS Trust; University College London Hospitals; Cambridge... and other collaboratorsRecruitingEgg Allergy | Food Allergy | Food Allergy in Children | Milk Allergy | Food Allergy in Infants | Nut Allergy | Food Allergen SensitisationUnited Kingdom
-
King's College LondonGuy's and St Thomas' NHS Foundation TrustUnknownEgg Allergy | Food Allergy | Food Allergy in Children | Milk Allergy | Food Allergy in Infants | Nut Allergy | Food Allergen SensitisationUnited Kingdom
-
Stanford UniversityRecruitingFood Allergy | Food Allergy in ChildrenUnited States
-
Rhode Island HospitalCompletedFood Allergy in Children
-
University Hospital, MontpellierUnknownFood Allergy Suspected | Food Allergy ProvedFrance
-
Rhode Island HospitalVirtually Better, Inc.CompletedFood Allergy in Children
Clinical Trials on Abrocitinib
-
PfizerActive, not recruitingAtopic DermatitisIndia
-
Innovaderm Research Inc.Not yet recruiting
-
PfizerActive, not recruitingDermatitis, AtopicChina, United States, Spain, Taiwan, Germany, Australia, Canada, Hungary, Korea, Republic of, Poland, Serbia, Bulgaria, Czechia, Japan, Latvia, United Kingdom, Belgium, Israel, Italy, Finland, Mexico, Romania, Slovakia, Argentina, Brazil, Chil... and more
-
PfizerAvailableAtopic DermatitisTaiwan, United States, Australia, Austria, Belgium, Canada, Greece, Mexico, Netherlands, Russian Federation, Spain, Switzerland
-
William DamskyYale University; PfizerActive, not recruiting
-
PfizerIn Expanded Access, treating physicians are the SponsorAvailableSevere Uncontrolled Atopic Dermatitis
-
National Institute of Diabetes and Digestive and...PfizerRecruitingDiabetes Mellitus, Type 1United States
-
PfizerCompletedAtopic DermatitisSpain, Taiwan, United States, Korea, Republic of, Poland, Canada, Australia, Hungary, Germany, Latvia, Finland, Chile, Bulgaria, Slovakia, Italy